 Blood Screening Market Insights, Competitive Landscape, and Market Forecast - 2033
The global Blood Screening Market is gaining strong traction as healthcare systems worldwide prioritize safe transfusion practices and early detection of infectious diseases. The market is expected... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global Blood Screening Market is gaining strong traction as healthcare systems worldwide prioritize safe transfusion practices and early detection of infectious diseases. The market is expected to be valued at 3.7 billion in 2026 and is projected to reach 7.9 billion by 2033, expanding at a CAGR of 11.50% during the forecast period. Blood screening technologies are essential in identifying pathogens in donated blood, thereby preventing the transmission of life-threatening infections. Increasing regulatory oversight and rising healthcare awareness are reinforcing the importance of advanced screening solutions across hospitals, blood banks, and diagnostic centers.Market Insights Blood screening has evolved into a critical diagnostic process supported by continuous technological advancements. The growing burden of infectious diseases such as hepatitis B, hepatitis C, and HIV has significantly increased the need for accurate and efficient screening methods. Modern techniques including nucleic acid amplification testing and chemiluminescence immunoassays are improving detection sensitivity and reducing diagnostic errors. In addition, automation in laboratories is streamlining workflows, enhancing throughput, and minimizing human intervention. As healthcare providers aim to ensure high standards of patient safety, the adoption of innovative blood screening technologies continues to expand across developed and developing regions. Drivers A key factor driving the Blood Screening Market is the rising incidence of transfusion-transmitted infections, which has intensified the demand for reliable screening procedures. Governments and regulatory authorities are enforcing stringent safety protocols, compelling healthcare providers to adopt advanced diagnostic solutions. The increasing volume of surgical procedures and trauma cases is also contributing to higher blood transfusion rates, further driving the need for comprehensive screening systems. Additionally, advancements in molecular diagnostics and sequencing technologies are enhancing the accuracy and speed of testing, supporting market growth. Growing awareness campaigns regarding blood safety are also encouraging widespread adoption of screening practices. Business Opportunity The market presents promising growth opportunities, particularly in emerging economies where healthcare infrastructure is rapidly developing. Rising investments in diagnostic laboratories and healthcare facilities are creating favorable conditions for market expansion. Companies are focusing on developing affordable and scalable screening technologies to address the needs of resource-constrained regions. The shift toward decentralized healthcare and point-of-care testing is further opening new growth avenues. Moreover, strategic partnerships and technological collaborations among key industry participants are fostering innovation and enabling the introduction of next-generation screening platforms tailored to evolving healthcare demands. Region Analysis North America holds a dominant position in the Blood Screening Market due to its well-established healthcare infrastructure, early adoption of advanced diagnostic technologies, and strong regulatory environment. Europe also represents a significant market, supported by increasing awareness and government initiatives aimed at ensuring blood safety. The Asia Pacific region is anticipated to experience the fastest growth, driven by a large patient population, improving healthcare access, and rising investments in medical infrastructure. Meanwhile, Latin America and the Middle East and Africa are gradually expanding, supported by ongoing healthcare reforms and efforts to strengthen diagnostic capabilities in these regions. Key Players • Abbott Laboratories • Roche Diagnostics • Siemens Healthineers • Thermo Fisher Scientific • Bio Rad Laboratories • Danaher Corporation (Beckman Coulter & Cepheid) • Becton, Dickinson and Company (BD) • BioMérieux • Grifols, S.A. • Ortho Clinical Diagnostics • Hologic, Inc. • QuidelOrtho Corporation • Hoffmann La Roche Ltd. • PerkinElmer, Inc. • Sysmex Corporation Segmentation By Technology: • Nucleic Acid Amplification Test (NAT) • ELISA • Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) • Next Generation Sequencing • Western Blotting By Product: • Reagent • Instrument By Region: • North America • Europe • Asia Pacific • Latin America • Middle East and Africa Table of Contents1. Executive Summary1.1. Global Blood Screening Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2026 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. COVID-19 Impact Analysis 2.5. Porter's Five Forces Analysis 2.6. Impact of Russia-Ukraine Conflict 2.7. PESTLE Analysis 2.8. Regulatory Analysis 2.9. Price Trend Analysis 2.9.1. Current Prices and Future Projections, 2025-2033 2.9.2. Price Impact Factors 3. Global Blood Screening Market Outlook, 2020-2033 3.1. Global Blood Screening Market Outlook, by Technology, Value (US$ Bn), 2020-2033 3.1.1. Nucleic Acid Amplification Test (NAT) 3.1.2. ELISA 3.1.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) 3.1.4. Next Generation Sequencing 3.1.5. Next Generation Sequencing 3.2. Global Blood Screening Market Outlook, by Product, Value (US$ Bn), 2020-2033 3.2.1. Reagent 3.2.2. Instrument 3.3. Global Blood Screening Market Outlook, by Region, Value (US$ Bn), 2020-2033 3.3.1. North America 3.3.2. Europe 3.3.3. Asia Pacific 3.3.4. Latin America 3.3.5. Middle East & Africa 4. North America Blood Screening Market Outlook, 2020-2033 4.1. North America Blood Screening Market Outlook, by Technology, Value (US$ Bn), 2020-2033 4.1.1. Nucleic Acid Amplification Test (NAT) 4.1.2. ELISA 4.1.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) 4.1.4. Next Generation Sequencing 4.1.5. Next Generation Sequencing 4.2. North America Blood Screening Market Outlook, by Product, Value (US$ Bn), 2020-2033 4.2.1. Reagent 4.2.2. Instrument 4.3. North America Blood Screening Market Outlook, by Country, Value (US$ Bn), 2020-2033 4.3.1. U.S. Blood Screening Market Outlook, by Technology, 2020-2033 4.3.2. U.S. Blood Screening Market Outlook, by Product, 2020-2033 4.3.3. Canada Blood Screening Market Outlook, by Technology, 2020-2033 4.3.4. Canada Blood Screening Market Outlook, by Product, 2020-2033 4.4. BPS Analysis/Market Attractiveness Analysis 5. Europe Blood Screening Market Outlook, 2020-2033 5.1. Europe Blood Screening Market Outlook, by Technology, Value (US$ Bn), 2020-2033 5.1.1. Nucleic Acid Amplification Test (NAT) 5.1.2. ELISA 5.1.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) 5.1.4. Next Generation Sequencing 5.1.5. Next Generation Sequencing 5.2. Europe Blood Screening Market Outlook, by Product, Value (US$ Bn), 2020-2033 5.2.1. Reagent 5.2.2. Instrument 5.3. Europe Blood Screening Market Outlook, by Country, Value (US$ Bn), 2020-2033 5.3.1. Germany Blood Screening Market Outlook, by Technology, 2020-2033 5.3.2. Germany Blood Screening Market Outlook, by Product, 2020-2033 5.3.3. Italy Blood Screening Market Outlook, by Technology, 2020-2033 5.3.4. Italy Blood Screening Market Outlook, by Product, 2020-2033 5.3.5. France Blood Screening Market Outlook, by Technology, 2020-2033 5.3.6. France Blood Screening Market Outlook, by Product, 2020-2033 5.3.7. U.K. Blood Screening Market Outlook, by Technology, 2020-2033 5.3.8. U.K. Blood Screening Market Outlook, by Product, 2020-2033 5.3.9. Spain Blood Screening Market Outlook, by Technology, 2020-2033 5.3.10. Spain Blood Screening Market Outlook, by Product, 2020-2033 5.3.11. Russia Blood Screening Market Outlook, by Technology, 2020-2033 5.3.12. Russia Blood Screening Market Outlook, by Product, 2020-2033 5.3.13. Rest of Europe Blood Screening Market Outlook, by Technology, 2020-2033 5.3.14. Rest of Europe Blood Screening Market Outlook, by Product, 2020-2033 5.4. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Blood Screening Market Outlook, 2020-2033 6.1. Asia Pacific Blood Screening Market Outlook, by Technology, Value (US$ Bn), 2020-2033 6.1.1. Nucleic Acid Amplification Test (NAT) 6.1.2. ELISA 6.1.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) 6.1.4. Next Generation Sequencing 6.1.5. Next Generation Sequencing 6.2. Asia Pacific Blood Screening Market Outlook, by Product, Value (US$ Bn), 2020-2033 6.2.1. Reagent 6.2.2. Instrument 6.3. Asia Pacific Blood Screening Market Outlook, by Country, Value (US$ Bn), 2020-2033 6.3.1. China Blood Screening Market Outlook, by Technology, 2020-2033 6.3.2. China Blood Screening Market Outlook, by Product, 2020-2033 6.3.3. Japan Blood Screening Market Outlook, by Technology, 2020-2033 6.3.4. Japan Blood Screening Market Outlook, by Product, 2020-2033 6.3.5. South Korea Blood Screening Market Outlook, by Technology, 2020-2033 6.3.6. South Korea Blood Screening Market Outlook, by Product, 2020-2033 6.3.7. India Blood Screening Market Outlook, by Technology, 2020-2033 6.3.8. India Blood Screening Market Outlook, by Product, 2020-2033 6.3.9. Southeast Asia Blood Screening Market Outlook, by Technology, 2020-2033 6.3.10. Southeast Asia Blood Screening Market Outlook, by Product, 2020-2033 6.3.11. Rest of SAO Blood Screening Market Outlook, by Technology, 2020-2033 6.3.12. Rest of SAO Blood Screening Market Outlook, by Product, 2020-2033 6.4. BPS Analysis/Market Attractiveness Analysis 7. Latin America Blood Screening Market Outlook, 2020-2033 7.1. Latin America Blood Screening Market Outlook, by Technology, Value (US$ Bn), 2020-2033 7.1.1. Nucleic Acid Amplification Test (NAT) 7.1.2. ELISA 7.1.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) 7.1.4. Next Generation Sequencing 7.1.5. Next Generation Sequencing 7.2. Latin America Blood Screening Market Outlook, by Product, Value (US$ Bn), 2020-2033 7.2.1. Reagent 7.2.2. Instrument 7.3. Latin America Blood Screening Market Outlook, by Country, Value (US$ Bn), 2020-2033 7.3.1. Brazil Blood Screening Market Outlook, by Technology, 2020-2033 7.3.2. Brazil Blood Screening Market Outlook, by Product, 2020-2033 7.3.3. Mexico Blood Screening Market Outlook, by Technology, 2020-2033 7.3.4. Mexico Blood Screening Market Outlook, by Product, 2020-2033 7.3.5. Argentina Blood Screening Market Outlook, by Technology, 2020-2033 7.3.6. Argentina Blood Screening Market Outlook, by Product, 2020-2033 7.3.7. Rest of LATAM Blood Screening Market Outlook, by Technology, 2020-2033 7.3.8. Rest of LATAM Blood Screening Market Outlook, by Product, 2020-2033 7.4. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Blood Screening Market Outlook, 2020-2033 8.1. Middle East & Africa Blood Screening Market Outlook, by Technology, Value (US$ Bn), 2020-2033 8.1.1. Nucleic Acid Amplification Test (NAT) 8.1.2. ELISA 8.1.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) 8.1.4. Next Generation Sequencing 8.1.5. Next Generation Sequencing 8.2. Middle East & Africa Blood Screening Market Outlook, by Product, Value (US$ Bn), 2020-2033 8.2.1. Reagent 8.2.2. Instrument 8.3. Middle East & Africa Blood Screening Market Outlook, by Country, Value (US$ Bn), 2020-2033 8.3.1. GCC Blood Screening Market Outlook, by Technology, 2020-2033 8.3.2. GCC Blood Screening Market Outlook, by Product, 2020-2033 8.3.3. South Africa Blood Screening Market Outlook, by Technology, 2020-2033 8.3.4. South Africa Blood Screening Market Outlook, by Product, 2020-2033 8.3.5. Egypt Blood Screening Market Outlook, by Technology, 2020-2033 8.3.6. Egypt Blood Screening Market Outlook, by Product, 2020-2033 8.3.7. Nigeria Blood Screening Market Outlook, by Technology, 2020-2033 8.3.8. Nigeria Blood Screening Market Outlook, by Product, 2020-2033 8.3.9. Rest of Middle East Blood Screening Market Outlook, by Technology, 2020-2033 8.3.10. Rest of Middle East Blood Screening Market Outlook, by Product, 2020-2033 8.4. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Vs Segment Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. Abbott Laboratories 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Developments 9.4.2. Roche Diagnostics 9.4.3. Siemens Healthineers 9.4.4. Thermo Fisher Scientific 9.4.5. Bio Rad Laboratories 9.4.6. Danaher Corporation (Beckman Coulter & Cepheid) 9.4.7. Becton, Dickinson and Company (BD) 9.4.8. BioMérieux 9.4.9. Grifols, S.A. 9.4.10. Ortho Clinical Diagnostics 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療機器）の最新刊レポート
Fairfield Market Research社の 医療機器分野 での最新刊レポート
本レポートと同じKEY WORD（blood）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
